Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 339 followers
Latest posts
Last updated about 13 hours ago
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
about 13 hours ago
Regeneron has hit the brakes on the phase 1/2a trial for an...
Merck KGaA lays off 20 staffers in latest blow to US research team
about 14 hours ago
The Massachusetts research site for Merck KGaA’s North American division, EMD Serono...
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
about 17 hours ago
Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger...
Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
about 18 hours ago
Evaxion has scrapped a next-gen solid tumor vaccine in order to channel...
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
about 19 hours ago
Antibody platform business OmniAb continues to rack up the Big Pharma partnerships...
Baylor Genetics hit by cybersecurity attack targeting patient, staff information
about 19 hours ago
Diagnostic genomics company Baylor Genetics has become the latest victim of a...
FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify
about 19 hours ago
Lantheus, which recently agreed to an $8 billion takeover by fellow radiopharma...
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
about 20 hours ago
Two recent patient deaths—both involving severe immune reactions to high-dose, viral vector-delivered...
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
about 23 hours ago
AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer...
Skye and Redx form new entity with $125M to advance fibrosis assets
4 days ago
Skye Bioscience has entered into an agreement to combine with privately held...
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
4 days ago
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away...
Capricor soars on plan to amend DMD filing after adcomm setback
4 days ago
Capricor Therapeutics has bounced back from a bruising FDA advisory committee meeting...